

## DAFTAR PUSTAKA

- American Cancer Society., (2016, September 13). Breast Cancer. Dipetik Januari 4, 2017, dari American Cancer Society: <http://www.cancer.org/acs/groups/cid/documents/webcontent/003090-pdf.pdf>
- Arslan N, Serdar M, Deveci S, Ozturk B, Narrin Y, Ilgan S, Ozturk E, Ozguren MA. Use of CA 15-3, CEA and Prolactin For The Primary Diagnosis of Breast Cancer and Correlation with The prognostic Factors at the time of initial diagnosis. Abstract. NCBI. Ann Nucl Med. 2000:Oct; 14(5): 395-9
- Aysola, K., Desai A., Welch, C., Xu, J., Qin, Y., Reddy, V., Matthews, R., Owens, C., Okoli, J., Beech D J., Piyathilake, C. J., Reddy, S. P., Rao, V. N., Triple Negative Breast Cancer-An Overview. Hereditary Genetics.2013
- Bland KI, Copeland EM. Editors. The Breast Comprehensive Management of Benign and Malignant Diseases. Philadelphia. WB Saunders company. 2009.
- Box, B.A., and Russel, C.A. 2009. Breast Cancer; in Manual of Clinical Oncology, 6<sup>th</sup> ed. Los Angeles: Lipincott Williams & Wilkins. p. 238-263.
- Compton, C. C., Byrd, R. D., Fritz, G. A., Greene, F. L., Trotti, A., AJCC Cancer Staging Atlas Second Edition. Springer.2012. 221-240
- Compton, Carolyn C., Byrd, David R., Garcia-Aguilar, Julio., Kurtzman, Scott H., Olawaiye, Alexander., and Washington, Mary Kay. 2012.

AJCC Cancer Staging Atlas Second Edition. Springer Science+Business Media, LLC , 32 : 419-440.

Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X., Zhan, J., Shi, B., Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer. Chongqing. China. 2015. 5(10);2929-2943

Desen, W. W.,. Buku Ajar Onkologi Klinis, edisi 2. Fakultas Kedokteran Universitas Indonesia. Jakarta. 2008. h; 365-383.

Dorit Laessig, Dorothea Nagel, Volker Heinemann, Importance of CEA and CA15-3 during Disease Progression in Metastatic Breast Cancer Patients, Anticancer Research 27: 1963-1968 (2007).

Geng, B., Liang, M. M., Ye, X. B., Zhao, W. Y., Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. Molecular and Clinical Oncology. China. 2014. Diakses dari <https://www.spandidos-publications.com/10.3892/mco.2014.419>

Ghoncheh, M., MahdaviFar, N., Darvishi, E., Salehiniya, H., Epidemiology, Incidence and Mortality of Breast Cancer in Asia. Asian Pac J Cancer Prev. 2016. 17: 47-52.

Globocan., International Agency for Research on Cancer ( IARC). Estimated Cancer Incidence Mortality and Prevalence Worldwide, Lyon 2012. Diakses dari <http://globocan.iarc.fr/Default.aspx>

Goldhirsch, A., Winer, E. P., Coates, A. S., Gelber, R. D., Piccart-Gebhart, M., Thürlimann, B., Sen, H.J., Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Annals of Oncology. 2013. 24: 2206–2223

Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, et al  
Editors. The AJCC Cancer Staging Manual. New York. 7 th Edition.  
2010.

Hashmi, A. A., Aijaz, S., Khan, S. M., Mahboob, R., Irfan, M., Zafar, N.  
I., Nisar, M., Siddiqui, M., Edhi, M. M., Faridi, N., Khan, A., Prognostic  
parameters of luminal A and luminal B intrinsic breast cancer subtypes  
of Pakistani patients. World Journal of Surgical Oncology. Kandahar.  
Afghanistan. 2018. 16:1

IARC, 2016. Globocan 2012: Estimated Cancer Incidence, Mortality And  
Prevalence Worldwide In 2012. [Http://www-Dep.Iarc.Fr/](http://www-dep.iarc.fr/), Globocan  
(August), 2012-2013. Retrieved From [www-dep.iarc.fr](http://www-dep.iarc.fr)

Jennifer J Rahn, Jing Zhang, Qiang Shen, Molecular Cancer Research:  
MUC1 Initiates Src-CrkL-Rac1/Cdc42-Mediated Actin Cytoskeletal  
Protrusive Motility after Ligating Intercellular Adhesion Molecule-1,  
2008, 6: 555-567.

Kemenkes, 2015. Situasi Penyakit Kanker : 4 Februari-Hari Kanker  
Sedunia. <http://www.depkes.go.id/resources/download/pusdatin/infodatin/infodatin-kanker.pdf>. Diunduh pada 13 Agustus 2017.

Keyhani M, Nasizadeh S, Dehghannejad A; Serum CA 15-3 Measurement  
in Breast Cancer Patients Before and After Mastectomy, Archives of  
Iranian Medicine, Volume 8, Number 4, 2005;263-66.

Kumar, V., Cotran, R. S., & Robbins, S. L. Payudara. Dalam V. Kumar, R.  
S. Cotran, & S. L. Robbins, Buku Ajar Patologi Edisi 7. EGC. Jakarta.  
2012. Vol. 2. Hal 759-800

- Li, L. T., Jiang, G., Chen, Q., dan Zheng, J. N., Ki67 is a promising molecular target in the diagnosis of cancer.2014. <https://www.spandidos-publications.com/10.3892/mmr.2014.2914>. Diakses: 5 Mei 2018
- M. Zegarac, S. Nikolic, D. Gavrilovic, M. Jevric, D. Kolarevic, Z. Nikolic-Tomasevic, M.Kocic, I. Djurisc, Z. Inic, V. Ilic, N. Santrac, Prognostic factors for longer disease free survival and overall survival after surgical resection of isolated liver metastasis from breast cancer. *JBUON* 2013; 18(4): 859-865
- Manuaba, T.W. 2010. Panduan Penatalaksanaan Kanker Payudara. Panduan Penatalaksanaan Kanker Solid Peraboi 2010. Jakarta: Sagung Seto. h. 17-48.
- McPherson, K., Steel, C.M. and Dixon, J.M. 2000. ABC of Breast Diseases, Breast Cancer-Epidemiology, Risk Factors, and Genetics. *British Medical Journal*. 321: 624-628.
- Phipps, A. I., Li, C. I., Breast Cancer Biology and Clinical Characteristics Breast Cancer Epidemiology. Springer Science and Business Media, LLC 2010.
- Rakha,E.A, Reis-Filho,J.S.,Baehner, F.,Dabbs, D.J., Decker, T., Eusebi, V., and Ellis, I.O.2010. Breast Cancer Prognostic Classification in the Molecular Era : The Role of Histological Grade. *Breast Cancer Research : BCR*, 12(4), 207. <https://doi.org/10.1186/bcr2607>
- Sergio Daniel Simon, José Bines, Gustavo Werutsky, Characteristics and prognosis of stage I-III breast cancer subtypes in Brazil: The AMAZONA retrospective cohort study, *The Breast*,Volume 44, 2019, Pages 113-119, ISSN 0960-9776,

- Soni, A., Ren, Z., Hameed, O., Chanda, D., Morgan, C. J., Siegal, G. P., Wei Shi. Breast Cancer Subtypes Predispose the Site of Distant Metastases. *American Journal Clinical Pathology*. 2015. 143;471-478
- Sorlie. (2007). Molecular classification of breast tumor: toward improved diagnostic and treatment. 91-114.
- Tampellini M, Berruti A, Gerbino A, et al : Relationship between CA 15-3 serum levels and disease extent in predicting overall survival of breast cancer patients with newly diagnosed metastatic disease. *British Journal of Cancer* 1997: 75 (5), 698-702.
- Yersal, O., Barutca, S., Biological Subtypes of Breast Cancer: Prognostic and Therapeutic Implications. *World Journal Clinical Oncology*. .2014. 5(3);412-24
- Yinghao Su, Ying Zheng, Wei Zheng, Kai Gu, Zhi Chen, Guoliang li, Qiuyin Cai, Wei Lu, Xiao Ou Su Distinct distribution and prognostic significance of molecular subtype of breast cancer in Chinese woman: a population-based cohort study (2011) 292
- Yulianto, R. Korelasi Kadar Her-2 Serum dengan Status Her-2 Jaringan Pada Penderita Kanker Payudara Stadium Lanjut Lokal dan Stadium Metastasis di Makassar, 2013.
- Zaha, D. C., Significance of Immunohistochemistry in Breast Cancer. *World Journal Clinical Oncology*. 2014. 5(3); 382-92
- Zhang, M. H., Man, H. T., Zhao, X. D., Dong, N., Ma, S. L., Estrogen receptor-positive breast cancer molecular signatures and therapeutic potentials. *Shenyang Agricultural University*. Shenyang. China. 2013. 2;41-52